Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Teclistimab Demonstrates Continued Deep, Durable Responses in Long-Term Follow-Up
Long-term follow-up of MajesTEC-1 trial shows teclistamab maintains deep and durable responses in relapsed/refractory multiple myeloma, with 63% overall response rate and 46.1% achieving CR or better. Median DOR, PFS, and OS increased to 24, 11.4, and 22.2 months, respectively. Safety profile consistent, with notable decrease in severe infections over time.
Related Clinical Trials:
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi
FYB202/Otulfi® received EC approval for subcutaneous and intravenous formulations, approved for Crohn’s disease, psoriasis, and psoriatic arthritis. Formycon and Fresenius Kabi announce EC marketing authorization for FYB202/Otulfi®, a biosimilar to Stelara®, valid in all EEA countries.
AbbVie's Parkinson's Drug Tavapadon: A Market Perform Rating Amidst Competitive
Leerink Partners' David Risinger maintains a Hold rating on AbbVie (ABBV) stock, citing positive Phase 3 tavapadon trial results but cautious about sales projections, remaining trials, and market competition.
Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI® in RRMM patients shows high response rates and durable responses
Janssen-Cilag announced updated Phase 1b RedirecTT-1 study results for TALVEY® and TECVAYLI® combination in RRMM patients, showing high response rates and durable responses with a manageable safety profile. The study highlights potential benefits for patients with extramedullary disease, offering a promising off-the-shelf treatment option.
Breakthrough for Advanced Myeloma? Talquetamab/Teclistamab Delivers Durable Responses
Talquetamab-tgvs plus teclistamab-cqyv showed a 79.5% overall response rate in triple-class exposed relapsed/refractory multiple myeloma patients, with 52.3% achieving complete response or better. The combination therapy demonstrated a manageable safety profile, with 69.8% progression-free survival at 18 months.
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
J&J's Talvey shows promise in multiple myeloma trials; FDA advisory committee votes against cancer immunotherapy use in certain digestive tract cancers; AbbVie's acquisition of Cerevel Therapeutics yields positive Parkinson's drug results; Roche's Gazyva succeeds in lupus nephritis Phase 3 study; Biogen terminates agreement with Sage Therapeutics over failed essential tremor drug; Enanta Pharmaceuticals' EDP-323 shows rapid antiviral effect against RSV.
Novel combination of TALVEY® (talquetamab) and TECVAYLI®
Updated RedirecTT-1 study results show talquetamab and teclistamab combination yields high response rates and durable responses in relapsed or refractory multiple myeloma patients, with a safety profile consistent to each monotherapy.
Related Clinical Trials:
RIT Co-op Experience Paves Way for Thriving Pharmaceutical Career
Sayali Kadam, a biotechnology student at RIT, leveraged the co-op program to gain industry experience at Johnson & Johnson and Bristol Myers Squibb, discovering her true career path. After graduating, she pursued a Master's at Carnegie Mellon, transitioning into pharmaceutical marketing. Today, she serves as Director of Launch Strategy and Operations at Merck, attributing her success to RIT's scientific foundation, real-world experience, and leadership development.
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) Shows Significant Reduction in Death Risk for Multiple Myeloma Patients
Cilta-cel, a CAR-T therapy, showed a 45% reduction in death risk vs standard therapies for lenalidomide-refractory multiple myeloma patients, with significant overall survival improvement. Presented at the 2024 International Myeloma Society meeting, it marks a potential shift in treatment paradigms.
Tulisokibart bests placebo, may yield 'important clinical benefit' via TL1A blockade in UC
Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.
© Copyright 2025. All Rights Reserved by MedPath